Lowe Brockenbrough & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-4,670
| Closed | -$256K | – | 255 |
|
|
2022
Q2 | $256K | Sell |
4,670
-600
| -11% | -$33.1K | 0.02% | 244 |
|
|
2022
Q1 | $291K | Buy |
5,270
+640
| +14% | +$34.8K | 0.02% | 240 |
|
|
2021
Q4 | $258K | Buy |
4,630
+344
| +8% | +$17.9K | 0.02% | 235 |
|
|
2021
Q3 | $208K | Hold |
4,286
| – | – | 0.02% | 266 |
|
|
2021
Q2 | $213K | Buy |
+4,286
| New | +$206K | 0.02% | 220 |
|
|
2020
Q4 | – | Sell |
-4,286
| Closed | -$202K | – | 213 |
|
|
2020
Q3 | $202K | Buy |
4,286
+80
| +2% | +$4.01K | 0.03% | 203 |
|
|
2020
Q2 | $214K | Sell |
4,206
-160
| -4% | -$8.21K | 0.03% | 197 |
|
|
2020
Q1 | $207K | Hold |
4,366
| – | – | 0.03% | 192 |
|
|
2019
Q4 | $256K | Buy |
4,366
+160
| +4% | +$8.9K | 0.03% | 197 |
|
|
2019
Q3 | $224K | Hold |
4,206
| – | – | 0.03% | 204 |
|
|
2019
Q2 | $210K | Sell |
4,206
-100
| -2% | -$5.02K | 0.03% | 204 |
|
|
2019
Q1 | $225K | Hold |
4,306
| – | – | 0.03% | 198 |
|
|
2018
Q4 | $206K | Hold |
4,306
| – | – | 0.03% | 187 |
|
|
2018
Q3 | $216K | Hold |
4,306
| – | – | 0.03% | 201 |
|
|
2018
Q2 | $217K | Sell |
4,306
-840
| -16% | -$42.3K | 0.03% | 195 |
|
|
2018
Q1 | $251K | Hold |
5,146
| – | – | 0.04% | 186 |
|
|
2017
Q4 | $228K | Sell |
5,146
-400
| -7% | -$18.5K | 0.03% | 189 |
|
|
2017
Q3 | $281K | Hold |
5,546
| – | – | 0.04% | 180 |
|
|
2017
Q2 | $299K | Sell |
5,546
-1,751
| -24% | -$93.3K | 0.05% | 171 |
|
|
2017
Q1 | $385K | Buy |
7,297
+991
| +16% | +$50.3K | 0.06% | 163 |
|
|
2016
Q4 | $304K | Hold |
6,306
| – | – | 0.05% | 169 |
|
|
2016
Q3 | $340K | Sell |
6,306
-80
| -1% | -$4.39K | 0.06% | 161 |
|
|
2016
Q2 | $346K | Sell |
6,386
-8,636
| -57% | -$455K | 0.06% | 159 |
|
|
2016
Q1 | $761K | Sell |
15,022
-80
| -0.5% | -$3.98K | 0.13% | 127 |
|
|
2015
Q4 | $762K | Sell |
15,102
-292
| -2% | -$14.9K | 0.13% | 131 |
|
|
2015
Q3 | $740K | Sell |
15,394
-123
| -0.8% | -$6.4K | 0.13% | 133 |
|
|
2015
Q2 | $808K | Buy |
15,517
+30
| +0.2% | +$1.69K | 0.13% | 137 |
|
|
2015
Q1 | $893K | Sell |
15,487
-57
| -0.4% | -$3.27K | 0.14% | 135 |
|
|
2014
Q4 | $830K | Buy |
15,544
+240
| +2% | +$13.4K | 0.13% | 137 |
|
|
2014
Q3 | $879K | Sell |
15,304
-700
| -4% | -$42.9K | 0.14% | 126 |
|
|
2014
Q2 | $1.07M | Sell |
16,004
-88
| -0.5% | -$5.96K | 0.17% | 115 |
|
|
2014
Q1 | $1.07M | Sell |
16,092
-80
| -0.5% | -$5.41K | 0.18% | 109 |
|
|
2013
Q4 | $1.08M | Hold |
16,172
| – | – | 0.18% | 111 |
|
|
2013
Q3 | $1.01M | Buy |
16,172
+60
| +0.4% | +$3.86K | 0.18% | 109 |
|
|
2013
Q2 | $1.01M | Buy |
+16,112
| New | +$1.02M | 0.19% | 106 |
|
Other funds holding GSK
Lowe Brockenbrough & Co's GSK Position: Q3 2022 in Review
Lowe Brockenbrough & Co sold out of GSK (GSK) in Q3 2022, closing a stake of 4,670 shares — an estimated $256K sold.
Lowe Brockenbrough & Co first reported a position in GSK in Q2 2013 and held it in 35 quarters. The position peaked at $1.08M in Q4 2013. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- Lowe Brockenbrough & Co reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
- Lowe Brockenbrough & Co sold 4,670 GSK shares in Q3 2022, an estimated $256K.
- Lowe Brockenbrough & Co first reported a position in GSK in Q2 2013 and held it in 35 quarters.
- Lowe Brockenbrough & Co's GSK position peaked at $1.08M in Q4 2013.
- 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on Lowe Brockenbrough & Co's 13F filing for Q3 2022, filed 1 Nov 2022.